The U.S. FDA approved Eli Lilly’s once-daily oral GLP-1 obesity drug orforglipron, branded Foundayo, giving the company a direct shot at Novo Nordisk’s oral weight-loss offering after Novo’s Wegovy pill launch. The approval clears Foundayo for adults with obesity or overweight plus at least one weight-related comorbidity, in combination with a reduced-calorie diet and increased physical activity. Foundayo follows a fast-moving review path tied to the FDA’s commissioner’s voucher program and is expected to ship shortly, positioning Lilly to compete in a category increasingly focused on convenient dosing. In comparative trial readouts highlighted by the companies, both daily oral regimens delivered meaningful weight reduction, but head-to-head superiority hasn’t been established. The approval intensifies the pricing and access battleground in obesity care, where insurers and telehealth channels shape real-world uptake. Lilly and Novo have already been signaling consumer-facing affordability strategies for cash-pay patients and insured populations. For biotech stakeholders, the move reinforces that oral incretin delivery is no longer an R&D bet but an active commercial contest—one that could pull forward additional oral obesity pipeline timelines across the industry.